A Dataset of Healthcare Utilization in Patients with Psoriasis and Psoriatic Arthritis and Risk of Osteoarthritis

We analyzed the timing of treatment initiation, which was classified into four intervals following the initial diagnosis: within 90 days, 91-180 days, 181-270 days, and 271-365 days. The treatments under evaluation included a range of topical agents, systemic therapies, and biologic agents.Topical agents included clobetasol, tacrolimus, betamethasone, calcipotriene, salicylic acid, pimecrolimus, and anthralin.

Systemic therapies consisted of methotrexate, cyclosporine, apremilast, and acitretin. The biologic agents assessed were etanercept, secukinumab, infliximab, adalimumab, ustekinumab, guselkumab, ixekizumab, tildrakizumab, brodalumab, certolizumab pegol, risankizumab, and bimekizumabThe primary outcome measured was the extent of healthcare utilization by these patients after at least three months of treatment. The types of healthcare visits considered included ambulatory visits, emergency visits, and inpatient encounters.